“…In the DSM-5 (American Psychiatric Association, 2013), RBD is placed within the group 'other specified depressive disorder': to meet the diagnosis, depressive episodes must be characterized by at least five symptoms and must be associated with functional impairment, but should last less than 14 days. However, the only large randomized placebo-controlled trial, of the selective serotonin reuptake inhibitor fluoxetine in patients with RBD and repeated suicide attempts, found no evidence of efficacy (Montgomery et al, 1994), and treatment studies with paroxetine have also yielded disappointing results (Kasper et al, 1995): there is a persistent need for additional placebo-controlled treatment studies in clinical samples (Baldwin, 2003). Case reports and small case series suggest that patients with RBD may benefit from treatment with nimodipine (Pazzaglia et al, 1993), tranylcypromine (Joffe, 1996), mirtazapine (Stamenkovic et al, 1998), lithium (Corominas et al, 1998), fluoxetine (Stamenkovic et al, 2001), reboxetine (Pezawas et al, 2002), lamotrigine (Ravindran and Ravindran, 2007) and olanzapine (De la Fuente, 2008).…”